Article: P03 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN A BELGIAN SURVEY

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma